NasdaqGS:DLO
NasdaqGS:DLODiversified Financial

DLocal (NasdaqGS:DLO) Stabilizes with 24% Stock Price Gain in Last Quarter

DLocal (NasdaqGS:DLO) has experienced a 24% price increase last quarter, aligning positively with recent corporate developments. The appointment of Will Pruett as an Independent Board Member enhances the board's expertise, likely supporting investor confidence. Additionally, the conclusion of the company's buyback plan, which saw the repurchase of approximately 4% of its stock, may have strengthened shareholder value perceptions. These actions coincide with a 1.7% market gain over the last...
NYSE:HIMS
NYSE:HIMSHealthcare

Hims & Hers Health (NYSE:HIMS) Faces Class Action After Partnership Termination With Novo Nordisk

Hims & Hers Health (NYSE:HIMS) has experienced a tumultuous quarter, marked by Novo Nordisk's termination of their collaboration after allegations of unsafe practices, resulting in a 35% drop in the company's share price. This partnership termination, alongside a class action lawsuit alleging misleading statements about safety and operational risks, contributed to heightened market volatility. Despite a remarkable quarterly earnings report with substantial sales and net income growth, these...
NYSE:FUBO
NYSE:FUBOInteractive Media and Services

fuboTV (NYSE:FUBO) Announces Multi-Year Deal With Weigel For Expanded Channel Lineup

fuboTV (NYSE:FUBO) recently announced a multi-year partnership with Weigel Broadcasting Co., enhancing its content offerings with seven new networks, which potentially contributed to an 11% rise in its share price over the last quarter. During this period, fuboTV also reported strong Q1 earnings, with significant revenue growth and a return to profitability, potentially bolstering investor confidence. Additionally, the launch of innovative viewing features and new sports partnerships expanded...
NasdaqGM:IOVA
NasdaqGM:IOVABiotechs

Iovance Biotherapeutics (NasdaqGM:IOVA) Announces CFO Resignation

Iovance Biotherapeutics (NasdaqGM:IOVA) recently experienced executive change, with CFO Jean-Marc Bellemin announcing his resignation effective July 10, 2025, following his June 10 decision to pursue other opportunities. Additionally, the Journal of Clinical Oncology published final results from a key clinical trial concerning their T cell therapy, Amtagvi, for advanced melanoma. Despite these developments, Iovance's stock remained flat over the past month. This stability contrasts with a...